Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment

Long-term clinical effectiveness of ustekinumab in patients with Crohn’s disease who failed biological therapies: a national cohort study

(2019) Claire Liefferinckx et al.   Journal of Crohns & Colitis

Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study

(2019) Aurelien Amiot et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry

(2019) M. Iborra et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence

(2019) Tal Engel et al.   DIGESTIVE AND LIVER DISEASE

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease

(2019) Mark Löwenberg et al.   GASTROENTEROLOGY

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease

(2019) Stephen B Hanauer et al.   Journal of Crohns & Colitis

Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

(2019) Vince B C Biemans et al.   Journal of Crohns & Colitis

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study

(2019) Vince B.C. Biemans et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study

(2018) Johan Burisch et al.   GUT

Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn’s Disease Patients

(2018) Cristiano Pagnini et al.   Gastroenterology Research and Practice

An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients

(2018) Paweł Kawalec et al.   Journal of Comparative Effectiveness Research

Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

(2017) Bruce E. Sands et al.   INFLAMMATORY BOWEL DISEASES

Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis

(2017) Tal Engel et al.   Journal of Crohns & Colitis

Improvements in the Long-Term Outcome of Crohn’s Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort

(2016) Steven F G Jeuring et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

(2012) Christina Ha et al.   Clinical Gastroenterology and Hepatology

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

(2011) Peter C. Austin   MULTIVARIATE BEHAVIORAL RESEARCH